Background Background Few controlled studies
Few controlled studies examine the treatment of depressive examine the treatment of depressive features in mania. features in mania.
Aims Aims To evaluate the efficacy of
To evaluate the efficacy of olanzapine, in combination with lithium olanzapine, in combination with lithium or valproate, for treating depressive or valproate, for treating depressive symptoms associated with mania. symptoms associated with mania.
Method Method Secondary analysis of a
Secondary analysis of a 6 -week, double-blind, randomised study 6 -week, double-blind, randomised study of olanzapine (5^20 mg/day) or placebo of olanzapine (5^20 mg/day) or placebo combined with ongoing valproate or combined with ongoing valproate or lithium open treatment for 344 patients lithium open treatment for 344 patients in mixed or manic episodes.This analysis in mixed or manic episodes.This analysis focused on a dysphoric subgroup with focused on a dysphoric subgroup with baseline Hamilton Rating Scale for baseline Hamilton Rating Scale for Depression (HRSD) total scores of 20 Depression (HRSD) total scores of 20 or over contrasted with non-dysphoric or over contrasted with non-dysphoric patients. patients.
Results

Results In the dysphoric subgroup
In the dysphoric subgroup ( (n n¼85) mean HRSD total score 85) mean HRSD total score improvement was significantly greater in improvement was significantly greater in olanzapine co-therapy patients than in olanzapine co-therapy patients than in those receiving placebo plus lithium or those receiving placebo plus lithium or valproate ( valproate (P P5 50.001). Substantial 0.001). Substantial contributors to this superiority included contributors to this superiority included the HRSD Maier sub-scale ( the HRSD Maier sub-scale (P P¼0.013) and 0.013) and the suicide item ( the suicide item (P P¼0.001).Total Young 0.001).Total Young Mania Rating Scale improvement was also Mania Rating Scale improvement was also superior with olanzapine co-therapy. superior with olanzapine co-therapy.
Conclusions Conclusions In patients with acute
In patients with acute dysphoric mania, addition of olanzapine to dysphoric mania, addition of olanzapine to ongoinglithium or valproate monotherapy ongoinglithium or valproate monotherapy significantly improved depressive significantly improved depressive symptom, mania and suicidality ratings. symptom, mania and suicidality ratings. Despite the fact that dysphoric symptoms Despite the fact that dysphoric symptoms represent a significant complicating factor represent a significant complicating factor in the successful treatment of bipolar in the successful treatment of bipolar disorder, controlled trials regarding the disorder, controlled trials regarding the depressive aspects of acute mania are rare depressive aspects of acute mania are rare (Montgomery (Montgomery et al et al, 2000) . A , 2000) . A post hoc post hoc anaanalysis of pooled data from two double-blind, lysis of pooled data from two double-blind, placebo-controlled trials supported the effiplacebo-controlled trials supported the efficacy of olanzapine monotherapy for both cacy of olanzapine monotherapy for both manic and depressive aspects of dysphoric manic and depressive aspects of dysphoric mania (Baker mania (Baker et al et al, 2003) , although the de-, 2003) , although the decrease in scores on the Hamilton Rating crease in scores on the Hamilton Rating Scale for Depression (HRSD; Hamilton, Scale for Depression (HRSD; Hamilton, 1967) was driven by improvement in items 1967) was driven by improvement in items related to sleep, insight and paranoia. A ranrelated to sleep, insight and paranoia. A randomised double-blind, placebo-controlled domised double-blind, placebo-controlled study demonstrated the efficacy of olanzastudy demonstrated the efficacy of olanzapine co-therapy in patients with bipolar dispine co-therapy in patients with bipolar disorder who had inadequate responses to order who had inadequate responses to valproate or lithium monotherapy (Tohen valproate or lithium monotherapy (Tohen et al et al, 2002) . We describe a secondary ana-, 2002). We describe a secondary analysis of data from that study, assessing both lysis of data from that study, assessing both depression and manic treatment responses depression and manic treatment responses among dysphoric and non-dysphoric among dysphoric and non-dysphoric patients with bipolar I disorder, who patients with bipolar I disorder, who received either olanzapine or placebo in received either olanzapine or placebo in addition to lithium or valproate. addition to lithium or valproate.
Declaration of interest
METHOD METHOD
Study design Study design
Data were derived from a large, multiData were derived from a large, multicentre double-blind study. Patients whose centre double-blind study. Patients whose symptoms of mania were partially nonsymptoms of mania were partially nonresponsive to 2 weeks of treatment with responsive to 2 weeks of treatment with valproate or lithium monotherapy at theravalproate or lithium monotherapy at therapeutic serum levels were randomised to peutic serum levels were randomised to receive either adjunctive olanzapine (herereceive either adjunctive olanzapine (hereafter referred to as 'combination therapy') after referred to as 'combination therapy') or adjunctive placebo ('monotherapy') in or adjunctive placebo ('monotherapy') in addition to their existing lithium or addition to their existing lithium or valproate monotherapy. We report secondvalproate monotherapy. We report secondary ary post hoc post hoc analyses focusing on a analyses focusing on a subgroup of patients with mania or mixed subgroup of patients with mania or mixed disorder who had substantial comorbid disorder who had substantial comorbid depression at baseline, and examine depression at baseline, and examine whether therapeutic response in this whether therapeutic response in this 'dysphoric' group differed from the remain-'dysphoric' group differed from the remaining 'non-dysphoric' patients. The study was ing 'non-dysphoric' patients. The study was conducted at 33 sites in the USA and 5 sites conducted at 33 sites in the USA and 5 sites in Canada. Detailed methods and the in Canada. Detailed methods and the primary results of this study have been primary results of this study have been published by Tohen published by Tohen et al et al (2002 Tohen et al et al ( ). (2002 .
Patients Patients
The protocol was approved by the instiThe protocol was approved by the institutional review board at each site, and all tutional review board at each site, and all patients provided written informed consent patients provided written informed consent prior to administration of any study proceprior to administration of any study procedures or study medications. At enrolment, dures or study medications. At enrolment, all patients had bipolar I disorder as defined all patients had bipolar I disorder as defined by DSM-IV criteria (American Psychiatric by DSM-IV criteria (American Psychiatric Association, 1994), manic or mixed epiAssociation, 1994), manic or mixed episode, with or without psychotic features, sode, with or without psychotic features, assessed independently of the symptom ratassessed independently of the symptom rating scale scores. Diagnosis was confirmed ing scale scores. Diagnosis was confirmed using the patient version of the Structured using the patient version of the Structured Clinical Interview for DSM-IV (SCID-P; Clinical Interview for DSM-IV (SCID-P; First First et al et al, 1997). Patients were required , 1997). Patients were required to have had at least two previous depressed, to have had at least two previous depressed, manic or mixed episodes, and to have had manic or mixed episodes, and to have had documented treatment with lithium or documented treatment with lithium or valproate for at least 2 weeks prior to visit valproate for at least 2 weeks prior to visit 1, with a therapeutic blood level of lithium 1, with a therapeutic blood level of lithium (0.6-1.2 mmol/l) or valproate (50-125 (0.6-1.2 mmol/l) or valproate (50-125 m mg/ g/ ml) at visit 1. Patients were included in ml) at visit 1. Patients were included in the study only if they showed inadequate the study only if they showed inadequate response to monotherapy for the 2 weeks response to monotherapy for the 2 weeks prior to randomisation, evidenced by a prior to randomisation, evidenced by a total score of 16 or more on the Young total score of 16 or more on the Young Mania Rating Scale (YMRS; Young Mania Rating Scale (YMRS; Young et al et al, , 1978) . After meeting entry criteria, patients 1978). After meeting entry criteria, patients were randomised in a 2:1 ratio to receive were randomised in a 2:1 ratio to receive either adjunctive olanzapine (flexible daily either adjunctive olanzapine (flexible daily dosage of 5, 10 or 20 mg) or adjunctive dosage of 5, 10 or 20 mg) or adjunctive placebo in conjunction with their current placebo in conjunction with their current valproate or lithium for 6 weeks. Olanzavalproate or lithium for 6 weeks. Olanzapine was initiated at a daily dosage of pine was initiated at a daily dosage of 10 mg. Plasma levels of lithium or valproate 10 mg. Plasma levels of lithium or valproate were documented to be within their therawere documented to be within their therapeutic serum ranges. peutic serum ranges.
Patients were also permitted adjunctive Patients were also permitted adjunctive benzodiazepine ( benzodiazepine (4 42 mg daily of lorazepam 2 mg daily of lorazepam equivalents) for no more than 14 days equivalents) for no more than 14 days cumulatively. Aside from the study drugs, cumulatively. Aside from the study drugs ,  benzodiazepines  and  anticholinergics  benzodiazepines  and  anticholinergics  (benzatropine mesilate,  (benzatropine mesilate, 4 42 mg per day), 2 mg per day), no other psychotropic drug was permitted no other psychotropic drug was permitted during the study. during the study.
Assessments Assessments
Severity of illness was measured by the Severity of illness was measured by the 11-item YMRS and the 21-item HRSD. 11-item YMRS and the 21-item HRSD. Ratings were completed at baseline and Ratings were completed at baseline and weekly during therapy. The weekly during therapy. The post hoc post hoc analysis focused on patients with moderate analysis focused on patients with moderate 4 7 2 4 7 2 1997) . Changes in severity of , 1997). Changes in severity of depressive symptoms were assessed using depressive symptoms were assessed using the HRSD total score, HRSD Maier subthe HRSD total score, HRSD Maier subscale and HRSD individual items. The scale and HRSD individual items. The Maier sub-scale comprises six items: item Maier sub-scale comprises six items: item 1 (depressed mood), item 2 (guilt), item 7 1 (depressed mood), item 2 (guilt), item 7 (work and activities), item 8 (retardation), (work and activities), item 8 (retardation), item 9 (agitation) and item 10 (psychic item 9 (agitation) and item 10 (psychic anxiety) (Maier anxiety) (Maier et al et al, 1985) . , 1985) .
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Statistical method Statistical method
Comparisons of baseline demographic and Comparisons of baseline demographic and illness characteristics between patients with illness characteristics between patients with a baseline HRSD total score of 20 or above a baseline HRSD total score of 20 or above and patients with a score below 20 were and patients with a score below 20 were performed using analysis of variance performed using analysis of variance (ANOVA) with categorisation (dysphoric (ANOVA) with categorisation (dysphoric at baseline/non-dysphoric at baseline) in at baseline/non-dysphoric at baseline) in the model for continuous variables and the model for continuous variables and using Fisher's exact test for categorical variusing Fisher's exact test for categorical variables. Descriptive baseline demographic ables. Descriptive baseline demographic factors for the olanzapine and placebo factors for the olanzapine and placebo treatment groups were also tabulated. The treatment groups were also tabulated. The primary efficacy measure was the mean primary efficacy measure was the mean change from baseline to end-point (last obchange from baseline to end-point (last observation carried forward up to week 6) for servation carried forward up to week 6) for HRSD total score. The ANOVA was HRSD total score. . non-dysphoric), dysphoric categorisation-treatment and dysdysphoric categorisation-treatment and dysphoric categorisation-visit and the threephoric categorisation-visit and the threeway interaction of dysphoric categorisationway interaction of dysphoric categorisationtreatment-visit. An unstructured covariance treatment-visit. An unstructured covariance matrix was fitted to the within-patient matrix was fitted to the within-patient repeated measures. Using contrasts within repeated measures. Using contrasts within the repeated measures model, the main the repeated measures model, the main overall effect of treatment within each dysoverall effect of treatment within each dysphoric subgroup was assessed, as was the phoric subgroup was assessed, as was the change from baseline to each visit between change from baseline to each visit between treatment groups. treatment groups.
Patients were analysed on an intentionPatients were analysed on an intentionto-treat basis for all analyses. Patients with to-treat basis for all analyses. Patients with a baseline assessment and at least one posta baseline assessment and at least one postbaseline measurement were included in the baseline measurement were included in the analysis. The YMRS and HRSD total scores analysis. The YMRS and HRSD total scores were derived from the individual items; if were derived from the individual items; if any single item was missing, the total score any single item was missing, the total score was treated as missing. All was treated as missing. All P P values were values were based on two-tailed tests with a significance based on two-tailed tests with a significance level of 0.05. level of 0.05.
RESULTS RESULTS
Patients Patients
Baseline patient and illness characteristics Baseline patient and illness characteristics by dysphoric/non-dysphoric categorisation by dysphoric/non-dysphoric categorisation and treatment group are summarised in and treatment group are summarised in Table 1 . Of 344 randomised patients, 85 Table 1 . Of 344 randomised patients, 85 met the study criterion for dysphoric mania met the study criterion for dysphoric mania (olanzapine combination treatment, (olanzapine combination treatment, n n¼60; 60; placebo monotherapy, placebo monotherapy, n n¼25) and 259 for 25) and 259 for non-dysphoric mania (combination treatnon-dysphoric mania (combination treatment, ment, n n¼169; monotherapy, 169; monotherapy, n n¼90). With-90). Within the dysphoric subgroup, 84.7% of in the dysphoric subgroup, 84.7% of patients met DSM-IV criteria for a mixed patients met DSM-IV criteria for a mixed episode. The dysphoric and non-dysphoric episode. The dysphoric and non-dysphoric groups contained similar proportions of groups contained similar proportions of patients being treated with valproate patients being treated with valproate (70.6% and 64.3% respectively, (70.6% and 64.3% respectively, P P¼0.356) 0.356) and lithium (29.4% and 35.7% respecand lithium (29.4% and 35.7% respectively) . Mean modal dose of olanzapine tively). Mean modal dose of olanzapine did not differ significantly between dysphodid not differ significantly between dysphoric and non-dysphoric patients (11.4 mg ric and non-dysphoric patients (11.4 mg v v. . 10.0 mg; 10.0 mg; P P¼0.15). 0.15).
Efficacy: depressive symptoms Efficacy: depressive symptoms
For the analysis of change in HRSD total For the analysis of change in HRSD total score from baseline to end-point, the interscore from baseline to end-point, the interaction between mood stabiliser (valproate action between mood stabiliser (valproate or lithium) and dysphoric categorisation or lithium) and dysphoric categorisation was not significant ( was not significant (P P¼0.290), indicating 0.290), indicating that the treatment effect of olanzapine comthat the treatment effect of olanzapine combination therapy over monotherapy was bination therapy over monotherapy was not dependent upon whether patients were not dependent upon whether patients were taking valproate or lithium. In addition, taking valproate or lithium. In addition, the main effect of mood stabiliser was also the main effect of mood stabiliser was also not significant ( not significant (P P¼0.528), indicating that 0.528), indicating that change in HRSD score did not differ in change in HRSD score did not differ in patients taking valproate patients taking valproate v v. those taking . those taking lithium. Since these two terms were not lithium. Since these two terms were not statistically significant, they were dropped statistically significant, they were dropped from the model for the analysis of HRSD from the model for the analysis of HRSD total score as well as the HRSD Maier total score as well as the HRSD Maier sub-scale and individual items. sub-scale and individual items.
For the HRSD total score, there was For the HRSD total score, there was a statistically significant interaction bea statistically significant interaction between categorisation (baseline dysphoric/ tween categorisation (baseline dysphoric/ non-dysphoric) and treatment group non-dysphoric) and treatment group ( (P P¼0.016), indicating that mean HRSD 0.016), indicating that mean HRSD score improvement in combination therapy score improvement in combination therapy patients over monotherapy patients differed patients over monotherapy patients differed between those with and without baseline between those with and without baseline dysphoria (Table 2 ). In both dysphoric dysphoria (Table 2 ). In both dysphoric and non-dysphoric patients, improvement and non-dysphoric patients, improvement in HRSD total score was significantly in HRSD total score was significantly greater for patients receiving combination greater for patients receiving combination therapy compared with monotherapy (dystherapy compared with monotherapy (dysphoric group phoric group 7 78.82 8.82 v v. . 7 71.42, 1.42, P P5 50.001; 0.001; non-dysphoric group non-dysphoric group 7 72.87 2.87 v v. 0.01, . 0.01, P P¼0.002). However, the magnitude of the 0.002). However, the magnitude of the difference between combination and monodifference between combination and monotherapy treatment groups was larger for the therapy treatment groups was larger for the dysphoric patients (Fig. 1) , thus driving the dysphoric patients (Fig. 1) , thus driving the significant interaction. The difference significant interaction. The difference between treatment groups is also apparent between treatment groups is also apparent from a comparison of effect sizes for the from a comparison of effect sizes for the dysphoric patients (1.11) with that of dysphoric patients (1.11) with that of non-dysphoric patients (0.43). non-dysphoric patients (0.43).
A significant interaction existed A significant interaction existed between treatment and dysphoric subgroup, between treatment and dysphoric subgroup, indicating that treatment group differences indicating that treatment group differences were dependent upon patients' dysphoric were dependent upon patients' dysphoric status (dysphoric status (dysphoric v v. non-dysphoric).
. non-dysphoric). Furthermore, MMRM analysis detected a Furthermore, MMRM analysis detected a significant interaction between treatment significant interaction between treatment and visit, indicating that the response over and visit, indicating that the response over time differed between the treatment groups time differed between the treatment groups ( (P P¼0.009). Plots of changes in mean HRSD 0.009). Plots of changes in mean HRSD total scores over time for dysphoric and total scores over time for dysphoric and non-dysphoric subgroups are presented in non-dysphoric subgroups are presented in Fig. 1 . For each subgroup, an overall Fig. 1 . For each subgroup, an overall treatment difference was detected (olanzatreatment difference was detected (olanzapine combination therapy superior to pine combination therapy superior to monotherapy; monotherapy; P P5 50.001 in both cases) and 0.001 in both cases) and this difference was observed as early as the this difference was observed as early as the first post-randomisation visit (week 1). first post-randomisation visit (week 1).
Analysis of the HRSD Maier sub-scale Analysis of the HRSD Maier sub-scale revealed no significant interaction between revealed no significant interaction between dysphoric categorisation and treatment, dysphoric categorisation and treatment, indicating that the beneficial effect of comindicating that the beneficial effect of combination therapy over monotherapy was bination therapy over monotherapy was similar in dysphoric and non-dysphoric similar in dysphoric and non-dysphoric patients. In both groups, improvement in patients. In both groups, improvement in Maier sub-scale score was significantly Maier sub-scale score was significantly greater for patients receiving olanzapine greater for patients receiving olanzapine combination therapy than for those receivcombination therapy than for those receiving monotherapy ( (Table 2 ). For each of individual items (Table 2 ). For each of these five items, dysphoric patients rethese five items, dysphoric patients receiving olanzapine combination therapy ceiving olanzapine combination therapy demonstrated significantly superior demonstrated significantly superior improvement over those receiving monoimprovement over those receiving monotherapy, corresponding to large effect sizes. therapy, corresponding to large effect sizes.
In contrast, patients in the non-dysphoric In contrast, patients in the non-dysphoric category exhibited no significant difference category exhibited no significant difference for these five items and small effect sizes for these five items and small effect sizes between treatment groups. In the case of between treatment groups. In the case of item 10 (psychic anxiety), significant item 10 (psychic anxiety), significant between-treatment differences were between-treatment differences were observed in both dysphoric and nonobserved in both dysphoric and nondysphoric patient groups. For HRSD items dysphoric patient groups. For HRSD items 1 (depressed mood) and 2 (feelings of guilt), 1 (depressed mood) and 2 (feelings of guilt), effect sizes were approximately 0.45 for effect sizes were approximately 0.45 for both subgroups -however, significant both subgroups -however, significant treatment differences were only seen in treatment differences were only seen in the non-dysphoric group, possibly owing the non-dysphoric group, possibly owing to the smaller size of the dysphoric group. to the smaller size of the dysphoric group.
In the case of HRSD items 20 (paranoid In the case of HRSD items 20 (paranoid symptoms) and 21 (obsessional and comsymptoms) and 21 (obsessional and compulsive symptoms), significant differences pulsive symptoms), significant differences were detected between combination and were detected between combination and monotherapy in the dysphoric patient monotherapy in the dysphoric patient group, whereas in the non-dysphoric group group, whereas in the non-dysphoric group there was a significant difference between there was a significant difference between treatment groups for item 20 only. treatment groups for item 20 only.
Efficacy: manic symptoms Efficacy: manic symptoms Analysis of YMRS total score revealed Analysis of YMRS total score revealed no significant interaction between mood no significant interaction between mood stabiliser (valproate or lithium) and stabiliser (valproate or lithium) and 4 74 4 74 4. Statistical tests performed between total columns and not between treatment groups; means analysed using a type III sum of squares analysis of variance with categorisation in 4. Statistical tests performed between total columns and not between treatment groups; means analysed using a type III sum of squares analysis of variance with categorisation in model and frequencies analysed using Fisher's exact test. model and frequencies analysed using Fisher's exact test. 5. Mixed type was defined by investigators using DSM^IV criteria, independently of mood rating scale scores. 5. Mixed type was defined by investigators using DSM^IV criteria, independently of mood rating scale scores. 6. Of the patients who showed psychotic features, 85.5% of the dysphoric individuals and 76.3% of the non-dysphoric were mood congruent. 6. Of the patients who showed psychotic features, 85.5% of the dysphoric individuals and 76.3% of the non-dysphoric were mood congruent. 7. Rapid cycling defined as four or more manic, depressed or mixed episodes in the previous year. 7. Rapid cycling defined as four or more manic, depressed or mixed episodes in the previous year. 8. Cochran^Armitage trend test. 8. Cochran^Armitage trend test. treatment, or in the main effect of mood treatment, or in the main effect of mood stabiliser ( stabiliser (P P4 40.20 for both), indicating 0.20 for both), indicating that the difference in treatment group rethat the difference in treatment group response was not dependent upon whether sponse was not dependent upon whether patients were receiving valproate or patients were receiving valproate or lithium. Furthermore, no statistically siglithium. Furthermore, no statistically significant interaction existed between nificant interaction existed between dysphoric/non-dysphoric categorisation and dysphoric/non-dysphoric categorisation and treatment ( treatment (P P¼0.111; Table 2), indicating 0.111; Table 2 ), indicating that improvements in mania severity for comthat improvements in mania severity for combination therapy over monotherapy were bination therapy over monotherapy were independent of dysphoric/non-dysphoric independent of dysphoric/non-dysphoric categorisation. Statistically significant categorisation. Statistically significant differences were detected between treatdifferences were detected between treatment groups for both dysphoric and nonment groups for both dysphoric and nondysphoric categories. The difference bedysphoric categories. The difference between treatment groups was numerically tween treatment groups was numerically (although not significantly) larger for the (although not significantly) larger for the dysphoric patients (interaction dysphoric patients (interaction P P¼0.111). 0.111).
However, this was due primarily to a larger However, this was due primarily to a larger monotherapy response among non-dysphoric monotherapy response among non-dysphoric patients (mean change for dysphoric patients patients (mean change for dysphoric patients 7 74.65 4.65 v v. non-dysphoric patients . non-dysphoric patients 7 79.78; 9.78; P P¼0.013) rather than a significant differ-0.013) rather than a significant difference in combination treatment response beence in combination treatment response between groups (mean change for dysphoric tween groups (mean change for dysphoric patients patients 7
711.75 11.75 v v. non-dysphoric patients . non-dysphoric patients 7 713.06; 13.06; P P¼0.361). 0.361). ) . A substantial proportion of the score). A substantial proportion of the treatment benefits in depression occurred treatment benefits in depression occurred within core mood symptoms. Significant within core mood symptoms. Significant improvements were also observed in mania improvements were also observed in mania symptom severity (YMRS total score) in the symptom severity (YMRS total score) in the combination therapy group compared with combination therapy group compared with the monotherapy group. the monotherapy group. Although defined rather differently, the Although defined rather differently, the terms 'dysphoric mania', 'depressive mania' terms 'dysphoric mania', 'depressive mania' and 'mixed mania' are used somewhat and 'mixed mania' are used somewhat interchangeably, as each describes a manic interchangeably, as each describes a manic episode complicated by prominent comorepisode complicated by prominent comorbid depressive features (Bauer bid depressive features (Bauer et al et al, 1994; , 1994; Akiskal Akiskal et al et al, 1998; Dilsaver , 1998; Dilsaver et al et al, 1999; , 1999;  4 7 5 4 7 5 
DISCUSSION DISCUSSION
Perugi Perugi et al et al, 2001). Given that patients , 2001
). Given that patients experiencing these dysphoric manic epiexperiencing these dysphoric manic episodes are reported to constitute up to sodes are reported to constitute up to two-thirds of bipolar disorder clinical samtwo-thirds of bipolar disorder clinical samples (Akiskal ples (Akiskal et al et al, 2000) , it might be , 2000), it might be expected that effective treatment options expected that effective treatment options would exist. However, the overall progwould exist. However, the overall prognosis for patients with dysphoric mania is nosis for patients with dysphoric mania is worse than for those with pure mania worse than for those with pure mania (Himmelhoch & Garfinkel, 1986; Keller (Himmelhoch & Garfinkel, 1986; Keller et al et al, 1986; Secunda , 1986; Secunda et al et al, 1987), and in fact , 1987) , and in fact our data at baseline (see Table 1 ) indicate our data at baseline (see Table 1 ) indicate greater severity of many variables in the greater severity of many variables in the dysphoric group. dysphoric group.
A key treatment challenge in bipolar A key treatment challenge in bipolar disorder, especially among patients with disorder, especially among patients with mixed mania and rapid cycling, is to bring mixed mania and rapid cycling, is to bring about improvement of symptoms of one about improvement of symptoms of one mood pole without worsening or acceleratmood pole without worsening or accelerating the onset of symptoms of the opposite ing the onset of symptoms of the opposite pole. Ideally, one medication would be pole. Ideally, one medication would be employed to treat both mood symptom employed to treat both mood symptom poles simultaneously. However, so far poles simultaneously. However, so far controlled monotherapy studies have failed controlled monotherapy studies have failed to demonstrate that this goal has been to demonstrate that this goal has been achieved, especially in mixed or dysphoric achieved, especially in mixed or dysphoric mania. Among the classic mood stabilisers, mania. Among the classic mood stabilisers, the body of evidence suggesting antidepresthe body of evidence suggesting antidepressant effects during lithium monotherapy is sant effects during lithium monotherapy is much less robust than that supporting its much less robust than that supporting its antimanic properties, and valproate may antimanic properties, and valproate may be preferable to lithium in the treatment be preferable to lithium in the treatment of dysphoric mania (McElroy of dysphoric mania (McElroy et al et al, 1988; , 1988; Freeman Freeman et al et al, 1992; Swann , 1992; Swann et al et al, 1997) . , 1997). For valproate, evidence of efficacy is stronFor valproate, evidence of efficacy is stronger for manic features than for depressive ger for manic features than for depressive features of dysphoric mania (Swann features of dysphoric mania (Swann et al et al, , 1997 ). Olanzapine's antimanic properties 1997). Olanzapine's antimanic properties are well established (Tohen are well established (Tohen et al et al, 2000) . , 2000). In addition, olanzapine appears to reduce In addition, olanzapine appears to reduce symptoms of bipolar depression, albeit less symptoms of bipolar depression, albeit less effectively when given alone than in combieffectively when given alone than in combination with fluoxetine (Tohen nation with fluoxetine (Tohen et al et al, 2003 (Tohen et al et al, , 2003a . ). In an earlier study we described the efficacy In an earlier study we described the efficacy of olanzapine monotherapy in treating both of olanzapine monotherapy in treating both manic and depressive symptoms in dysphomanic and depressive symptoms in dysphoric and non-dysphoric in-patients (Baker ric and non-dysphoric in-patients (Baker et et al al, 2003) . Olanzapine demonstrated signif-, 2003) . Olanzapine demonstrated significant improvement in YMRS total score icant improvement in YMRS total score compared with placebo in both dysphoric compared with placebo in both dysphoric and non-dysphoric patients, and also proand non-dysphoric patients, and also produced significant improvement in HRSD duced significant improvement in HRSD total score in the dysphoric group (Baker total score in the dysphoric group (Baker et al et al, 2003) . This is to our knowledge the , 2003). This is to our knowledge the only previous placebo-controlled demononly previous placebo-controlled demonstration of simultaneous improvement in stration of simultaneous improvement in depressive and manic symptoms of dysphodepressive and manic symptoms of dysphoric mania during treatment with a single ric mania during treatment with a single agent. Further study seemed appropriate, agent. Further study seemed appropriate, however, given that the previous report however, given that the previous report had important limitations, such as small had important limitations, such as small sample size and non-statistically significant sample size and non-statistically significant improvement in Maier sub-scale scores. improvement in Maier sub-scale scores.
Our analysis includes effect size calculaOur analysis includes effect size calculations. An effect size of 1.0 reflects differtions. An effect size of 1.0 reflects difference between treatment groups of the ence between treatment groups of the same magnitude as 1 standard deviation same magnitude as 1 standard deviation within the population. This can be transwithin the population. This can be translated into a probability statement that lated into a probability statement that indicates that the improvement in score of indicates that the improvement in score of an average individual in the comparison an average individual in the comparison group exceeds that of 84% of patients in group exceeds that of 84% of patients in the placebo group. Effect size is a useful the placebo group. Effect size is a useful tool for comparing findings across studies, tool for comparing findings across studies, and by convention an effect size of 0.2 is and by convention an effect size of 0.2 is considered small, 0.5 moderate and 0.8 or considered small, 0.5 moderate and 0.8 or greater large (Cohen, 1988) . This study greater large (Cohen, 1988) . This study demonstrated a large effect size (1.11) for demonstrated a large effect size (1.11) for improvement of depression in patients with improvement of depression in patients with baseline dysphoria who received olanzapine baseline dysphoria who received olanzapine in addition to lithium or valproate. in addition to lithium or valproate. Whereas our previous report did not Whereas our previous report did not demonstrate clear benefit in terms of Maier demonstrate clear benefit in terms of Maier core mood sub-scale, this study demoncore mood sub-scale, this study demonstrated a moderate effect size for this substrated a moderate effect size for this subscale (0.61). scale (0.61).
Our analyses have several limitations. Our analyses have several limitations. First, these are First, these are post hoc post hoc analyses of data analyses of data from a clinical trial which evaluated severfrom a clinical trial which evaluated severity of manic symptoms (YMRS total score) ity of manic symptoms (YMRS total score) as the primary efficacy measure. Second, as the primary efficacy measure. Second, assignment to valproate or lithium was assignment to valproate or lithium was not randomised but reflected the treatment not randomised but reflected the treatment preferences of clinicians and investigators. preferences of clinicians and investigators. Third, the study design lacked an olanzaThird, the study design lacked an olanzapine monotherapy arm, which makes it pine monotherapy arm, which makes it difficult to draw any conclusions regarding difficult to draw any conclusions regarding the relative contributions of olanzapine the relative contributions of olanzapine alone, or synergistic effects with the concoalone, or synergistic effects with the concomitant medication, to the overall treatment mitant medication, to the overall treatment benefits. In fact, no inference can be drawn benefits. In fact, no inference can be drawn regarding the relative merit of other treatregarding the relative merit of other treatments or combinations that were not ments or combinations that were not evaluated in this trial. For example, evaluated in this trial. For example, improvement on classical antipsychotic improvement on classical antipsychotic agents would be of interest, given that a agents would be of interest, given that a recent mania treatment comparison of recent mania treatment comparison of olanzapine and haloperidol did not estabolanzapine and haloperidol did not establish differential treatment response of lish differential treatment response of depressive symptoms among the small depressive symptoms among the small ( (n n¼19) subgroup with baseline HRSD 19) subgroup with baseline HRSD scores of 20 or over (Tohen scores of 20 or over (Tohen et al et al, 2003 (Tohen et al et al, , 2003b . ). Fourth, the high proportion of participants Fourth, the high proportion of participants in rapid-cycling disorder is notable. A in rapid-cycling disorder is notable. A rapid-cycling course may affect mania rapid-cycling course may affect mania phenomenology -for example, some 'dysphenomenology -for example, some 'dysphoric' patients may be in transition from phoric' patients may be in transition from mania to depression (Kraepelin, 1921; mania to depression (Kraepelin, 1921; Himmelhoch Himmelhoch et al et al, 1976; McElroy , 1976; McElroy et al et al, , 1992 ) -and its relationship to dysphoric 1992) -and its relationship to dysphoric mania is unclear (Himmelhoch mania is unclear (Himmelhoch et al et al, , 1976; Post 1976; Post et al et al, 1989; McElroy , 1989; McElroy et al et al, , 1992) . Finally, the subject group of interest 1992). Finally, the subject group of interest (patients with a baseline HRSD total score (patients with a baseline HRSD total score of 20 or above) was not defined of 20 or above) was not defined a priori a priori. . In this study most dysphoric patients were In this study most dysphoric patients were 4 7 6 4 7 6 diagnosed with mixed episodes, but interdiagnosed with mixed episodes, but interestingly there was imperfect homology estingly there was imperfect homology between a DSM-IV mixed mania diagnosis between a DSM-IV mixed mania diagnosis and dysphoric mania as defined by rating and dysphoric mania as defined by rating scales. The DSM-IV definition of a mixed scales. The DSM-IV definition of a mixed manic phase requires patients to simultamanic phase requires patients to simultaneously meet criteria for both a major neously meet criteria for both a major depressive episode and a manic episode. depressive episode and a manic episode. However, some argue that a DSM-IV synHowever, some argue that a DSM-IV syndromal approach may not be optimal for dromal approach may not be optimal for identifying patients with mania and cliniidentifying patients with mania and clinically important comorbid depressive cally important comorbid depressive features (Cassidy features (Cassidy et al et al, 1998; Cassidy & , 1998; Cassidy & Carroll, 2001; Dilsaver Carroll, 2001; Dilsaver et al et al, 1999), and , 1999) , and a number of proposals have been put a number of proposals have been put forward which attempt to provide a frameforward which attempt to provide a framework within which a diagnosis of dysphowork within which a diagnosis of dysphoric mania may be made (McElroy ric mania may be made (McElroy et al et al, , 1992; Perugi 1992; Perugi et al et al, 1997; Cassidy , 1997; Cassidy et al et al, , 2000; Akiskal 2000; Akiskal et al et al, 2003) . These propo-, 2003) . These proposals require the presence of a full manic sals require the presence of a full manic episode, plus the presence of two or three episode, plus the presence of two or three defined depressive symptoms. For the purdefined depressive symptoms. For the purpose of this study, in which all patients pose of this study, in which all patients met criteria for a manic episode, we used met criteria for a manic episode, we used a threshold HRSD total score of 20 or a threshold HRSD total score of 20 or over to define a group of patients displayover to define a group of patients displaying prominent depressive features. We ing prominent depressive features. We believe that this use of an objective rating believe that this use of an objective rating scale represents a clinically meaningful scale represents a clinically meaningful approach to identifying subjects. In the approach to identifying subjects. In the context of this clinical trial, the DSM-IV context of this clinical trial, the DSM-IV and HRSD categorisation systems are and HRSD categorisation systems are somewhat incongruent, with approxisomewhat incongruent, with approximately twice the number of patients being mately twice the number of patients being identified as 'mixed' as were categorised as identified as 'mixed' as were categorised as dysphoric based on symptom ratings. One dysphoric based on symptom ratings. One potential contribution to the incongruence potential contribution to the incongruence is that symptom ratings coincided with is that symptom ratings coincided with treatment randomisation, whereas diagtreatment randomisation, whereas diagnostic verification could have taken place nostic verification could have taken place up to a week prior to randomisation. In up to a week prior to randomisation. In any case, the dysphoric subgroup primarily any case, the dysphoric subgroup primarily included patients with diagnosis of a included patients with diagnosis of a mixed episode. mixed episode.
In conclusion, our analyses found that In conclusion, our analyses found that olanzapine in combination with either olanzapine in combination with either lithium or valproate was effective in lithium or valproate was effective in improving the severity of depressive sympimproving the severity of depressive symptoms coexisting with acute mania. Furthertoms coexisting with acute mania. Furthermore, olanzapine co-therapy with lithium more, olanzapine co-therapy with lithium or valproate also demonstrated efficacy in or valproate also demonstrated efficacy in the management of manic symptoms, the management of manic symptoms, irrespective of whether such symptoms irrespective of whether such symptoms were complicated by concurrent dysphoria. were complicated by concurrent dysphoria. Given the prognostic implications of dysGiven the prognostic implications of dysphoric features in mania, and the limited phoric features in mania, and the limited number of pharmacological options curnumber of pharmacological options currently available for such patients, prospecrently available for such patients, prospectively designed studies of combination tively designed studies of combination therapy with mood stabilisers and typical therapy with mood stabilisers and typical antipsychotics in the management of dysantipsychotics in the management of dysphoric mania are encouraged. Such studies phoric mania are encouraged. Such studies should consider innovative strategies for should consider innovative strategies for defining dysphoric mania that transcend defining dysphoric mania that transcend the limited perspective of DSM-IV mixed the limited perspective of DSM-IV mixed states (Perugi states (Perugi et al et al, 1997; Akiskal , 1997; Akiskal et al et al, , 2003 Tohen, M.,Vieta, E., Calabrese, J., Tohen, M.,Vieta, E., Calabrese, J., 
A rating scale for mania: reliability, validity and A rating scale for mania: reliability, validity and sensitivity. sensitivity. British Journal of Psychiatry British Journal of Psychiatry, , 133 133, 429^435. , 429^435.
